...We Welcome You To The Resverlogix HUB On AGORACOM!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** Trial is Fully Enrolled and Top-Line Results Expected Q1 2019

Free
Message: Eastern exercised some $0.90 cent warrants

Also interesting is that the shares and warrants Hepalink acquired in July 2015 were subject to a three year lock-up which recently expired (July 21st I think). The strike on those warrants is $2.67 which we only just recently surpassed.

RESVERLOGIX CLOSES $50 MILLION PRIVATE PLACEMENT WITH HEPALINK AND EASTERN CAPITAL

 

Share
New Message
Please login to post a reply